Comprehensive proteomic and pathological profiling identifies PRAS40 as a novel biomarker and mediator of primary immune checkpoint blockade resistance in non-small cell lung cancer

Immune checkpoint blockade (ICB) has revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), yet primary resistance remains a significant clinical challenge. Recent evidence implicates PRAS40 (AKT1S1) in regulating cellular survival and immune responses, but its role in immunotherapy resistance is not fully understood. Transcriptomic data from TCGA and GTEx cohorts were analyzed to assess PRAS40 expression. Prognostic value was evaluated using Cox regression. Immune microenvironment features were characterized with CIBERSORT and TIMER. Predictive efficacy for ICB response was examined using TIDE and IPS. Plasma PRAS40 levels in 66 NSCLC patients receiving ICB were quantified by proximity extension assay (PEA), and multiplex immunohistochemistry assessed associations among PRAS40, PD-L1, and CD8+ T cells in tumor tissues. High PRAS40 expression was associated with poor prognosis, reduced CD8+ T cell infiltration, and downregulation of immune checkpoint genes. Elevated circulating PRAS40 predicted primary ICB resistance and shorter progression-free survival, independent of PD-L1 or CD8+ T cell status. PRAS40 is strongly associated with primary ICB resistance in NSCLC and may serve as a novel predictive biomarker. These findings support its potential to guide personalized immunotherapy in lung cancer.

• Publication year

  2025

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2025-10-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-025-04166-1PMID 41071193PMCID 12514079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stage-specific regulation of undifferentiated spermatogonia by AKT1S1-mediated AKT-mTORC1 signaling during mouse spermatogenesis.

  2024cited by this paper
• Emerging discoveries on the role of TRIM14: from diseases to immune regulation

  2024cited by this paper
• Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1.

  2024cited by this paper
• Paeoniflorin inhibits PRAS40 interaction with Raptor to activate mTORC1 to reverse excessive autophagy in airway epithelial cells for asthma.

  2024cited by this paper
• Deciphering the potential role of PGRN in regulating CD8+ T cell antitumor immunity

  2024cited by this paper
• Tumor-suppressive miR-4732-3p is sorted into fucosylated exosome by hnRNPK to avoid the inhibition of lung cancer progression

  2024cited by this paper
• S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function

  2024cited by this paper
• PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil

  2023cited by this paper
• Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives

  2023cited by this paper
• Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.

  2023cited by this paper
• PGK1 represses autophagy-mediated cell death to promote the proliferation of liver cancer cells by phosphorylating PRAS40

  2022cited by this paper
• First-Line Immunotherapy for Non-Small-Cell Lung Cancer.

  2022cited by this paper
• Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

  2022cited by this paper
• Immune Checkpoint Inhibitors in Cancer Therapy

  2022cited by this paper
• TIFA promotes colorectal cancer cell proliferation in an RSK‐ and PRAS40‐dependent manner

  2022cited by this paper
• Non‐small cell lung cancer in China

  2022cited by this paper
• Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

  2022cited by this paper
• 4EBP1 senses extracellular glucose deprivation and initiates cell death signaling in lung cancer

  2022cited by this paper
• Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

  2021cited by this paper
• Targeting PRAS40: a novel therapeutic strategy for human diseases

  2021cited by this paper
• The Molecular Landscape and Biological Alterations Induced by PRAS40-Knockout in Head and Neck Squamous Cell Carcinoma

  2021cited by this paper
• Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.

  2021cited by this paper
• MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressants

  2021cited by this paper
• Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

  2020cited by this paper
• PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells

  2020cited by this paper
• Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma

  2020cited by this paper
• MELK is Upregulated in Advanced Clear Cell Renal Cell Carcinoma and Promotes Disease Progression by Phosphorylating PRAS40

  2019cited by this paper
• Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

  2019cited by this paper
• Structural Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40

  2017cited by this paper
• The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor

  2017cited by this paper
• Targeting PRAS40 for multiple diseases.

  2016cited by this paper
• Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

  2016cited by this paper

• No citing papers are available for this paper.